Crossmark

Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks

Published Online: 2024-11-15

Published Print: 2025-01

Authors

Diorio, Caroline

Teachey, David T.

Grupp, Stephan A. https://orcid.org/0000-0001-8030-7595
License Information

Text and Data Mining valid from 2024-11-15

Version of Record valid from 2024-11-15
More Information

Article History

Accepted: 14 October 2024

First Online: 15 November 2024

Competing interests

: D.T.T. serves on advisory boards (unpaid) for Amgen, BEAM Therapeutics, Janssen, Jazz Pharmaceuticals, Servier and Sobi; receives research funding from BEAM Therapeutics; and has patents pending relating to cytokine-release syndrome after chimeric antigen receptor (CAR) T cell therapy and to CD38-directed CAR T cells. S.A.G. receives research funding from Cellectis, Kite (a GILEAD company), Novartis, Servier and Vertex; consults for Adaptive Biotech, Eureka Therapeutics, Estrella Immunopharma, Jazz Pharmaceuticals and Novartis; and has advised for Allogene, Cabaletta Bio, Jazz Pharmaceuticals, Novartis, Verismo and Vertex, and has patents related to CAR T toxicity managed by the University of Pennsylvania. C.D. declares no competing interests.

Document is current